Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BINGO...Great ride!!!
EXAS sells (upsized) 9.78M* shares @$15.50—an 8% discount to yesterday’s close:
http://finance.yahoo.com/news/exact-sciences-announces-upsizing-pricing-120000500.html
*Assuming exercise of underwriter’s option.
EXAS selling 8.05M shares at unspecified price:
http://finance.yahoo.com/news/exact-sciences-announces-agreement-sell-200100578.html
*Assuming exercise of underwriter’s option.
EXAS 2Q16 results:
#msg-124123972
The maintained full-year 2016 guidance may be lowballing.
Just bought in w/750 shares. Go EXAS! Aloha.
EXAS-AWESOME RIDE!! Congrats all Holders..
In total break-out mode......wonder what the float is here?? Can't be much the way this is moving.
About to go $14+
EXAS-Making moves, but need some news..
crazy move to $14 after Failure to get BCBS approval
EXAS $13.7 kinda active AH on today's rumor
Harry has posted Charts of the Day video on EXAS at TheTechTrader site noting: Exact Sciences Corporation (EXAS) looks beautiful. On Thursday it popped on 10.5 million shares. That’s best volume in three weeks. It spiked up to 13.20, and pulled back a point, but it was still up 96 cents to 12.25, or 8.5%. Unfortunately, it didn’t close well, but it was a really nice session. Keep in mind that it’s gone from 5, and change, to 13 just in the last six weeks. I’m looking for 15 and 17 as the next targets on the stock. http://tinyurl.com/h9dna29
Is EXAS Eyeing 17.00, Sure look like it.
http://tinyurl.com/z6no59u
Harry has posted Charts of the Day video on EXAS at TheTechTrader site noting:Exact Sciences Corporation (EXAS) is doing well. Although it had that big spike up, it pulled back and held, and on Wednesday it had and inside day, up 36 cents to 10.35, or 3.6%, on 3.5 million shares. With volume acting stronger, I’m wondering if this is continuing to consolidate for another week or two, then go, where it immediately takes out 11 1/2 area, and then moves onto the 14 1/2 area. Eventually it may get a gap fill that takes it up to 18. It is 13.15 days to cover. http://tinyurl.com/jmy46ye
$EXAS-Looking AWESOME.. Those stupid clay charts are useless folks. Just a front to sell a BS CD. "How to be a millionaire"! I will tell you how to become a millionaire. Start with 3 million dollars, then it will magically turn into 1 million. Boom, Millionaire!!
$EXAS-Just bottomed then news!! BUY!!
10.32 lod gap & trap so far!!
23,900 @ 11.12 just now= $$$$$
$EXAS
USPSTF has apparently reversed its original (bearish) opinion of Cologuard and is now embracing the test:
https://twitter.com/Liquid_Biopsy/status/743038956548292608
Why Exact Sciences Stock Is Soaring 33% Today
Shares are rallying after a key new hire, and ahead of an investor conference.
http://finviz.com/quote.ashx?t=exas&ty=c&ta=1&p=d
What: After announcing recently that management hired a former Baird research analyst in a key role, and a day before presenting at William Blair's 36th annual growth stock conference, shares in Exact Sciences (NASDAQ:EXAS) surged 33% higher today.
So what: Exact Sciences shares are gaining ground, but today's rally follows a significant decline in the company's share price since the launch of Cologuard, the company's colon cancer screening test.
EXAS Chart
EXAS DATA BY YCHARTS.
The company didn't report any news today, but it did announce the appointment of Jeff Elliott to a senior role earlier this month, and management's calendar has been packed with investor conferences that could be factoring into the move higher.
Elliott, a former senior research analyst who covered the diagnostic and lab industries for Baird, is being tasked with identifying and pursuing strategic business opportunities for Exact Sciences, and while management didn't specifically say what opportunities Elliott will be evaluating, it could be that he's pursuing collaborations, licensing, or a business combination.
The company's Cologuard does very good job at screening for colon cancer, but winning reimbursement has been more challenging than expected, and despite a significant increase in screenings, spending continues to significantly outpace revenue. It's possible the hiring of Elliott signals that the C-suite is willing to entertain deals that could take some of the burden off of the company's balance sheet.
Exact Sciences has also been aggressively making its case with investors this month. On June 8, the company was at Goldman Sachs' 37th Annual Global Healthcare Conference, and on June 9, management presented at Jefferies Healthcare Conference. Tomorrow, CEO Kevin Conroy is scheduled to appear at William Blair's 36th Annual Growth Stock Conference in Chicago.
Now what: Sellers were holding 22% of the company's share float short entering today, and given today's move, it wouldn't be surprising if some sellers have decided to cover their positions ahead of tomorrow's presentation.
At this conference, management will probably reinforce the potential for a more than doubling in Cologuard tests and sales this year. Last year, the company completed 104,000 tests, and this year, management expects to complete more than 240,000 screenings. If Exact Sciences completes that many tests, it expects sales will reach at least $90 million, up from $39.4 million last year.
Overall, the potential to provide regular screenings to an increasingly larger and longer-living population of baby boomers has management pegging Cologuard's addressable market at $4 billion. That's undeniably a big market opportunity, but investors might want to temper some of their enthusiasm, because even if the company executes on its sales goals for 2016, it will still lose money. Total operating costs exited Q1 at an annualized $216 million.
Looks like a great day here. Have a good one all..
Flying PreMarket now $12+
The volume here is very very strong - this is not just a random pump. It could be another $EMES - I would actually buy and hold
* * $EXAS Video Chart 06-14-16 * *
Link to Video - click here to watch the technical chart video
EXAS -6% on tepid 1Q16 results: #msg-122374193.
EXAS presentation of "real-world" Cologuard data at AACR:
http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=875#.VxZyKZMrJTY
FDA approves Epigenomics’ “Epi proColon” blood test for colorectal cancer: #msg-121884384
EXAS looks lot like these guys Genenews Ltd. (PC) (GNWSF)both in the same space yet GeneNews has a $10 million market cap and EXAS a $700 million market cap. Things that make you go hmmmm!!!!
EXAS reports 4Q15 results/2016 guidance:
http://finance.yahoo.com/news/exact-sciences-reports-fourth-quarter-110000544.html
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
635
|
Created
|
10/19/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |